Baglioni and colleagues (2024) review the cellular composition of adipose tissue and report outcomes of autologous micrografts using small volumes of mechanically processed fat in chronic wounds that had not responded to advanced dressings.
The central finding: adipogenic progenitor cells (APCs) in the stromal fraction act primarily through paracrine effects — secreting VEGF, HGF, and TGF-β — without laboratory expansion. Collection takes place during liposuction under local anesthesia.
For LipAge partner physicians: the study reinforces that material collected during liposuction has a biologically relevant cellular profile, and that its preservation under qualified conditions is a topic of clinical interest.
For decades, adipose tissue was viewed as surgical waste — a byproduct of body contouring procedures. Scientific research over the past 20 years has changed that perception.
Baglioni et al. (2024) present morphological and functional data confirming that adipose tissue is dynamic and heterogeneous, comprising mature adipocytes, fibroblasts, endothelial cells, smooth muscle cells, macrophages, and — of particular clinical interest — adipogenic progenitor cells (APCs).
| Adipocytes | Metabolic and endocrine functions; release bioactive extracellular vesicles (adipokines, miRNAs) |
| APCs / preadipocytes | Mesodermal differentiation; involvement in tissue repair through paracrine effects |
| Endothelial cells | Angiogenesis; express CD31; approximately 30–40% of the stromal fraction |
| Pericytes | Vascular support; modulation of the local inflammatory response |
| Fibroblasts | Extracellular matrix remodeling; collagen and elastin synthesis |
| Hematopoietic cells | Immunomodulation; express CD45 |
Phenotypically, APCs express CD34, CD73, CD105, CD117, and CD90 — classic mesenchymal markers — and do not express CD31 or CD45. Their proliferative capacity in culture exceeds that of bone marrow stromal cells, with far less invasive access to the source tissue.
[FACT] Flow cytometry confirms the mesenchymal phenotype of APCs, using methodology published in independent studies (Kern et al., 2006; De Francesco et al., 2021).
The reported effect does not depend on direct cellular differentiation in most of the contexts studied. The dominant mechanism is paracrine: in response to stimuli such as hypoxia, cells secrete soluble factors that coordinate the local repair response.
The mechanisms above are described in the context of a literature review. Clinical use of adipose tissue is subject to current regulations from ANVISA (Brazil's health regulatory agency) and individual assessment by the attending physician.
The LipAge service is operated by Cryopraxis, a Cell Technology Center licensed by ANVISA, with a traceable chain of custody and AABB accreditation. The decision to use cryopreserved material always rests with the responsible physician.
The study used a demanding clinical model: chronic surgical wounds showing no tendency toward closure for more than 90 days, which had not responded to hydrogels, silver dressings, metalloproteinase inhibitors, and other second-line interventions. Patients received autologous micrografts (AMGs) of processed adipose tissue.
The Rigenera system was used for mechanical processing of small volumes — indicating that even small volumes of fat contain a relevant cell density. This aligns with LipAge's premise that material collected during liposuction has biological value.
[DATA-SUPPORTED HYPOTHESIS] The authors infer that the paracrine effect is the central mechanism observed. Randomized controlled studies are still needed to establish causality.
A secondary finding: combining adipose tissue with dermal fragments produced different outcomes from fat alone. Tissue microarchitecture may modulate the cellular niche and paracrine secretion.
For partner physicians: in settings where dermal tissue is available (flaps, scars, revisions), combining the two tissues is an active area of research, with no standardized protocol yet.
1. No randomized control group: limits causal inference; improvement may reflect selection bias or the effect of intensified follow-up.
2. Sample size: a hospital-based case series, not a multicenter trial.
3. Processing standardization: results from the Rigenera system cannot be directly extrapolated to other techniques.
4. Long-term follow-up: durability of the effect and recurrence were addressed only to a limited extent.
5. Individual variability: cellular composition varies with age, BMI, donor site, and comorbidities.
| Timing matters | Tissue collected on the day of liposuction carries the patient's biological profile at that time. Cryopreservation under qualified conditions maintains it for future use upon medical indication. |
| Processing quality | The reported effects depend on processing that preserves tissue viability and integrity. LipAge Score — Cryopraxis's Quality System — evaluates each sample before release. |
| Autologous use | The patient is both donor and recipient, eliminating concerns about compatibility between donors. |
✅ We can state: adipose tissue contains cells studied in indexed scientific literature for their involvement in repair processes. LipAge preserves this autologous material with traceability and quality control at a Cell Technology Center licensed by ANVISA.
✅ We can state: the decision to use cryopreserved material is a clinical one, made by the attending physician at a future date.
❌ We must not claim: any promise of outcomes, assurance of efficacy, or extrapolation from this or any individual article to the LipAge service.
| Title | Efficacy of Autologous Micrografting Technology (AMT) in the Treatment of Non-Healing Chronic Wounds |
| Authors | Baglioni et al. |
| Journal | Frontiers in Medicine, 2024 |
| DOI | 10.3389/fmed.2024.1417920 |
| Type | Prospective uncontrolled experimental study |
| Center | A.O.U. Città della Salute e della Scienza — Plastic Surgery, Turim, Italy |
| Period | November 2019 to December 2021 |